Literature DB >> 24152192

Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction.

Jin Liang1, Shoufu Tian, Junxia Han, Peihua Xiong.   

Abstract

AIMS: Renal fibrosis is a common outcome of chronic kidney disease. This study was designed to examine the protective effects of resveratrol (RSV) against renal fibrosis induced by unilateral ureteral obstruction (UUO). We also attempted to elucidate the potential mechanism involved.
METHODS: Mice were randomly divided into three groups: sham-operated, UUO, and UUO/RSV (20 mg·kg(-1)·day(-1)). Histological changes were examined using periodic acid-Schiff and Masson's trichrome staining after 14 days. Superoxide dismutase (SOD), malondialdehyde (MDA), and 8-OHdG levels were determined using a commercially available kit. ICAM-1, TNF-α, and TGF-β levels were measured using real-time PCR. Fibronectin levels were measured by western blot, and the Smad3 acetylation and Sirt1 were examined by immunoprecipitation and western blot.
RESULTS: Our study showed that RSV treatment significantly attenuated renal injury including extracellular matrix deposition and tubulointerstitium damage. Renal cortical mRNA levels of ICAM-1, TNF-α, and TGF-β, protein expression of fibronectin and Smad3 acetylation were significantly upregulated in the UUO group. However, treatment with RSV significantly decreased the expression of these proteins. Furthermore, RSV also decreased the levels of reactive oxygen species (ROS) including MDA and 8-OHdG, and increased the level of SOD, which protects cells against ROS damage.
CONCLUSION: Our findings suggest that RSV treatment inhibits oxidative stress, Smad3 acetylation, and renal interstitial fibrosis. Therefore, RSV may have potential as a therapeutic target for the treatment of chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24152192     DOI: 10.3109/0886022X.2013.844644

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  19 in total

1.  Resveratrol attenuates renal injury and fibrosis by inhibiting transforming growth factor-β pathway on matrix metalloproteinase 7.

Authors:  Zhou Xiao; Chen Chen; Ting Meng; Wenzheng Zhang; Qiaoling Zhou
Journal:  Exp Biol Med (Maywood)       Date:  2015-08-27

2.  Sirtuin1 Protects against Systemic Sclerosis-related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes.

Authors:  Haiyan Chu; Shuai Jiang; Qingmei Liu; Yanyun Ma; Xiaoxia Zhu; Minrui Liang; Xiangguang Shi; Weifeng Ding; Xiaodong Zhou; Hejian Zou; Feng Qian; Philip W Shaul; Li Jin; Jiucun Wang
Journal:  Am J Respir Cell Mol Biol       Date:  2018-01       Impact factor: 6.914

Review 3.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

Review 4.  Sirtuin 1: A Target for Kidney Diseases.

Authors:  Lili Kong; Hao Wu; Wenhua Zhou; Manyu Luo; Yi Tan; Lining Miao; Lu Cai
Journal:  Mol Med       Date:  2015-01-12       Impact factor: 6.354

5.  Resveratrol inhibits renal interstitial fibrosis in diabetic nephropathy by regulating AMPK/NOX4/ROS pathway.

Authors:  Ting He; Jiachuan Xiong; Ling Nie; Yanlin Yu; Xu Guan; Xinli Xu; Tangli Xiao; Ke Yang; Liang Liu; Daohai Zhang; Yunjian Huang; Jingbo Zhang; Junping Wang; Kumar Sharma; Jinghong Zhao
Journal:  J Mol Med (Berl)       Date:  2016-08-04       Impact factor: 4.599

6.  Identification of sirtuin 1 as a promising therapeutic target for hypertrophic scars.

Authors:  Xiao-Zhi Bai; Jia-Qi Liu; Long-Long Yang; Lei Fan; Ting He; Lin-Lin Su; Ji-Hong Shi; Chao-Wu Tang; Zhao Zheng; Da-Hai Hu
Journal:  Br J Pharmacol       Date:  2016-03-23       Impact factor: 8.739

7.  Disruption of cyclooxygenase type 2 exacerbates apoptosis and renal damage during obstructive nephropathy.

Authors:  Line Nilsson; Kirsten Madsen; Søren Krag; Jørgen Frøkiær; Boye L Jensen; Rikke Nørregaard
Journal:  Am J Physiol Renal Physiol       Date:  2015-10-14

Review 8.  An Organ System Approach to Explore the Antioxidative, Anti-Inflammatory, and Cytoprotective Actions of Resveratrol.

Authors:  Ashim Malhotra; Sundeep Bath; Fawzy Elbarbry
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

Review 9.  Resveratrol: why is it a promising therapy for chronic kidney disease patients?

Authors:  Juliana F Saldanha; Viviane de O Leal; Peter Stenvinkel; José Carlos Carraro-Eduardo; Denise Mafra
Journal:  Oxid Med Cell Longev       Date:  2013-12-29       Impact factor: 6.543

Review 10.  Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol.

Authors:  Shereen M Hamza; Jason R B Dyck
Journal:  Front Physiol       Date:  2014-08-05       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.